NO20072035L - Memantin for behandling av adferdsforstyrrelser hos barn - Google Patents
Memantin for behandling av adferdsforstyrrelser hos barnInfo
- Publication number
- NO20072035L NO20072035L NO20072035A NO20072035A NO20072035L NO 20072035 L NO20072035 L NO 20072035L NO 20072035 A NO20072035 A NO 20072035A NO 20072035 A NO20072035 A NO 20072035A NO 20072035 L NO20072035 L NO 20072035L
- Authority
- NO
- Norway
- Prior art keywords
- memantine
- children
- treatment
- behavioral disorders
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling av individer diagnostisert med en atferdsforstyrrelse i barndommen, f.eks. en forstyrrelse innen autismespektret eller oppmerksomhetssvikt/hyperaktivitetsforstyrrelse (ADHD) av kombinert type, ved tilførsel av en effektiv mengde memantin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61260004P | 2004-09-23 | 2004-09-23 | |
PCT/US2005/034199 WO2006034465A1 (en) | 2004-09-23 | 2005-09-23 | Memantine for the treatment of childhood behavioral disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072035L true NO20072035L (no) | 2007-06-13 |
Family
ID=35445934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072035A NO20072035L (no) | 2004-09-23 | 2007-04-20 | Memantin for behandling av adferdsforstyrrelser hos barn |
Country Status (16)
Country | Link |
---|---|
US (2) | US20060079582A1 (no) |
EP (1) | EP1799224A1 (no) |
JP (1) | JP2008514620A (no) |
KR (1) | KR20070046185A (no) |
CN (1) | CN101374525A (no) |
AR (1) | AR052643A1 (no) |
AU (1) | AU2005286672B2 (no) |
BR (1) | BRPI0515560A (no) |
CA (1) | CA2578953A1 (no) |
EA (1) | EA012036B1 (no) |
IL (1) | IL182105A0 (no) |
MX (1) | MX2007003267A (no) |
NO (1) | NO20072035L (no) |
TW (1) | TW200626160A (no) |
WO (1) | WO2006034465A1 (no) |
ZA (1) | ZA200702130B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7456224B2 (en) | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
EP2040676A2 (en) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
WO2009004440A2 (en) * | 2007-06-29 | 2009-01-08 | Orchid Chemicals & Pharmaceuticals Limited | Quick dissolve compositions of memantine hydrochloride |
US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
EP2138173A1 (en) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Pharmaceutical compositions comprising aminoadamantane derivatives |
EP2201950B1 (en) * | 2008-12-08 | 2016-11-16 | Biocodex | Compounds and methods for treating autism spectrum disorders |
IT1396556B1 (it) * | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
WO2012068161A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
WO2014015047A1 (en) | 2012-07-17 | 2014-01-23 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
UA107653U (uk) * | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
KR101424514B1 (ko) * | 2013-01-02 | 2014-07-31 | 건국대학교 산학협력단 | 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도 |
WO2014117089A1 (en) * | 2013-01-25 | 2014-07-31 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
WO2014153180A1 (en) * | 2013-03-14 | 2014-09-25 | Michela Gallagher | Methods and compositions for improving cognitive function |
EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
DK3297644T3 (da) * | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
CN108026107B (zh) | 2015-06-19 | 2021-07-30 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
EP4201427A1 (en) | 2016-08-24 | 2023-06-28 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
US11529319B2 (en) | 2017-08-01 | 2022-12-20 | Stuart A. Lipton | Methods and compositions for treating neurological conditions |
US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH603545A5 (no) * | 1972-04-20 | 1978-08-31 | Merz & Co | |
HU169986B (no) * | 1972-12-07 | 1977-03-28 | ||
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US6326226B1 (en) * | 1997-07-15 | 2001-12-04 | Lg. Philips Lcd Co., Ltd. | Method of crystallizing an amorphous film |
EP1047436B1 (en) * | 1998-01-13 | 2009-10-21 | Synchroneuron, LLC | N-acetylhomotaurinates for use in treating hyperkinesias |
WO2001041707A2 (en) * | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
US6727231B1 (en) * | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
CA2473536A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
TW200410672A (en) * | 2002-07-19 | 2004-07-01 | Merz Pharma Gmbh & Co Kgaa | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
-
2005
- 2005-09-23 WO PCT/US2005/034199 patent/WO2006034465A1/en active Application Filing
- 2005-09-23 EA EA200700708A patent/EA012036B1/ru not_active IP Right Cessation
- 2005-09-23 US US11/234,764 patent/US20060079582A1/en not_active Abandoned
- 2005-09-23 KR KR1020077006537A patent/KR20070046185A/ko not_active Application Discontinuation
- 2005-09-23 CA CA002578953A patent/CA2578953A1/en not_active Abandoned
- 2005-09-23 EP EP05802627A patent/EP1799224A1/en not_active Withdrawn
- 2005-09-23 TW TW094133147A patent/TW200626160A/zh unknown
- 2005-09-23 JP JP2007533663A patent/JP2008514620A/ja active Pending
- 2005-09-23 AU AU2005286672A patent/AU2005286672B2/en not_active Ceased
- 2005-09-23 CN CNA2005800321868A patent/CN101374525A/zh active Pending
- 2005-09-23 BR BRPI0515560-6A patent/BRPI0515560A/pt not_active IP Right Cessation
- 2005-09-23 MX MX2007003267A patent/MX2007003267A/es unknown
- 2005-09-26 AR ARP050103986A patent/AR052643A1/es not_active Application Discontinuation
-
2007
- 2007-03-13 ZA ZA200702130A patent/ZA200702130B/xx unknown
- 2007-03-21 IL IL182105A patent/IL182105A0/en unknown
- 2007-04-20 NO NO20072035A patent/NO20072035L/no not_active Application Discontinuation
-
2009
- 2009-10-30 US US12/609,105 patent/US20100081723A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR052643A1 (es) | 2007-03-28 |
IL182105A0 (en) | 2007-07-24 |
ZA200702130B (en) | 2008-09-25 |
EP1799224A1 (en) | 2007-06-27 |
US20100081723A1 (en) | 2010-04-01 |
KR20070046185A (ko) | 2007-05-02 |
BRPI0515560A (pt) | 2008-07-29 |
AU2005286672A1 (en) | 2006-03-30 |
MX2007003267A (es) | 2007-05-23 |
EA012036B1 (ru) | 2009-06-30 |
CA2578953A1 (en) | 2006-03-30 |
AU2005286672B2 (en) | 2009-03-12 |
WO2006034465A1 (en) | 2006-03-30 |
CN101374525A (zh) | 2009-02-25 |
WO2006034465A8 (en) | 2006-06-08 |
US20060079582A1 (en) | 2006-04-13 |
TW200626160A (en) | 2006-08-01 |
JP2008514620A (ja) | 2008-05-08 |
EA200700708A1 (ru) | 2007-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072035L (no) | Memantin for behandling av adferdsforstyrrelser hos barn | |
WO2005037203A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
NO20080246L (no) | Anti-IGF1R-antistofformuleringer | |
BR112014018592A2 (pt) | composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos | |
WO2007100777A3 (en) | Methods for the treatment of adhd and related disorders | |
UY31114A1 (es) | Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos | |
EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
BRPI0510224A (pt) | métodos de prevenção de doença autoimunológica e artigo industrializado | |
EA201001322A1 (ru) | Вакцины против хламидиоза | |
TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
BRPI0907135B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica | |
PL1974210T3 (pl) | Sposób diagnozowania wielotorbielowatości nerek | |
WO2006059252A3 (en) | Methods and fluorinated compositions for treating amyloid-related diseases | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
WO2008100727A3 (en) | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders | |
CY1110620T1 (el) | Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας | |
WO2006138372A3 (en) | Methods and reagents for the treatment of inflammatory disorders | |
NO20083751L (no) | Metoder for behandling av kognitive og andre sykdommer | |
WO2009032172A3 (en) | Platinum compositions as treatment for oct-related cancers | |
EP1899726A4 (en) | METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES | |
CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
UY29756A1 (es) | Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica. | |
SG165413A1 (en) | Pecam-1 genotype |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |